CA-NITRO-SOFTWARE
16.3.2023 01:05:39 CET | Business Wire | Press release
Nitro Software, a global leader in SaaS eSignature and PDF document solutions for businesses, announced today that Nitro Sign was again named a Leader in the GigaOm Radar Report for E-Signature Solutions.
Nitro Sign provides organizations with high-trust electronic signatures that meet or exceed global security and compliance standards, including multiple layers of protection and identity verification. The scalable solution also offers flexible integrations and APIs.
Identifying Nitro Sign as an industry Leader for the second year in a row, GigaOm acknowledged that the Nitro platform supports highly secure, end-to-end digital document processes with a seamless customer experience.
GigaOm’s 2023 Radar Report for E-Signature Solutions awarded Nitro Sign high scores for its:
- extensive compliance support, offering direct eID integration for over 30 jurisdictions
- leading data field configuration and analytics functionality
- best-in-class pricing tiers with minimal add-on fees
- automation and digitization across document workflows
- scalability and security due to its high-trust global data center strategy, extensive security provisions and tamper-proof seals at the signature (rather than envelope) level
GigaOm also noted that Nitro’s broad portfolio can support even the most complex use cases.
“The global adoption of eSignatures took off during the pandemic, and it only continues to accelerate,” said Nitro Chief Product Officer, Sam Thorpe. “Businesses of all sizes, around the world, benefit from the agility, efficiency and productivity eSignature technology enables. And while Nitro delivers a seamless customer experience, as the GigaOm Radar Report attests, there’s far more to our eSignature solutions than just enabling people to sign documents on their devices. Nitro has done the hard work behind the scenes to deliver an easy-to-use, high-trust solution that ensures our customers have the proper security, can avoid fraud and stay compliant.”
GigaOm’s Radar Report notes: “To be a significant player in this space, an e-signature solution must not only support the core e-signature process (preparation, distribution, execution) but also offer extensive compliance support, scalability for high-volume use cases, and flexibility across a range of countries, languages and interfaces. Functionality that simply allows a user to draw a signature on a document is not sufficient to be considered in this report.”
The report adds that “businesses are looking for end-to-end process capabilities rather than standalone solutions. In other words, e-signatures are viewed as a core component of broader document management suites, potentially not something an enterprise would purchase on its own. SMBs will shift more gradually to this strategy but will follow a similar path….”
In its 2023 Radar Report, GigaOm delivers comprehensive evaluations of 14 leading eSignature vendors, an analysis of each of their offerings and provides expert guidance on how to choose the right eSignature vendor for both small and medium business and enterprise requirements.
To read more about Nitro’s position and learn more about what’s happening with eSignatures, click here for a complimentary copy of the GigaOm Radar Report for E-Signature Solutions.
About Nitro Software
Nitro (ASX: NTO) is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its industry-leading analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
